Diferencia entre revisiones de «SGLT-2 Inhibitor»
(→Common) |
(Add See Also section) |
||
| (No se muestra una edición intermedia de otro usuario) | |||
| Línea 9: | Línea 9: | ||
===Serious=== | ===Serious=== | ||
*Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | *Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | ||
*Fournier's gangrene (rare) | |||
===Common=== | ===Common=== | ||
| Línea 18: | Línea 19: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule | *Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule | ||
==See Also== | |||
*[[Diabetes medications]] | |||
*[[Diabetic ketoacidosis]] | |||
*[[Hyperglycemia]] | |||
==References== | ==References== | ||
Revisión actual - 09:14 22 mar 2026
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule